<DOC>
	<DOCNO>NCT03011320</DOCNO>
	<brief_summary>This study look enroll subject ovarian cancer standard care surgery remove ovarian cancer tumor . The main aim study able observe EC1456 take broken inside tumor . The effect EC1456 tumor also study . This study also help u compare amount EC1456 see tumor tumor image 99mTc-etarfolatide single-photon emission tomography ( SPECT ) single-photon emission tomography in-line x-ray compute tomography ( SPECT/CT ) . All subject undergo 99mTc-etarfolatide SPECT SPECT/CT scan within 2 week prior EC1456 administration . Individual subject receive 1 follow 2 dos EC1456 pre-operatively : - 4 mg/m2 - 8 mg/m2 EC1456 administer 1 follow 2 time point : - &lt; 8 hour plan surgery - 48±4 hour plan surgery Blood collect pharmacokinetic ( PK ) study right EC1456 dose right surgery . At time surgery , tumor sample remove sent Endocyte analysis .</brief_summary>
	<brief_title>An Exploratory Study Folic Acid-tubulysin Conjugate EC1456 Ovarian Cancer Subjects Undergoing Surgery</brief_title>
	<detailed_description>Study EC1456-02 exploratory , open-label study seek enroll subject ovarian cancer undergo therapeutic debulking surgery . All subject undergo 99mTc-etarfolatide scan within 2 week prior EC1456 administration . Briefly , prior 99mTc-etarfolatide imaging procedure , subject receive one intravenous ( IV ) injection folic acid unlabeled etarfolatide , follow within 1 3 minute injection 99m Tc-etarfolatide ( i.e. , etarfolatide label 740 925 megabecquerels ( MBq ) [ 20 25 millicurie ( mCi ) ] sodium pertechnetate Tc-99m injection ) . Individual subject receive 1 follow 2 dos EC1456 pre-operatively : - 4 milligram ( mg ) /meter ( ) 2 - 8 milligram ( mg ) /meter ( ) 2 EC1456 administer 1 follow 2 time point : - &lt; 8 hour plan surgery - 48±4 hour plan surgery The 4 mg/m2 dose EC1456 administer &lt; 8 hour prior surgery first dose cohort enroll . Once enrollment cohort complete , remain cohort open enrollment . Assignment specific cohort determine Sponsor base data assess previously enrol subject . Two six subject enrol per cohort show . - Cohort 1 : 4 mg/m2 EC1456 &lt; 8 hour prior surgery - Cohort 2 : 4 mg/m2 EC1456 48±4 hour prior surgery - Cohort 3 : 8 mg/m2 EC1456 &lt; 8 hour prior surgery - Cohort 4 : 8 mg/m2 EC1456 48±4 hour prior surgery In event unexpected result , low , intermediate high EC1456 level 12.5 mg/m2 , high determine safe dose EC1456 define parallel phase I study EC1456-01 , may explore . The first on-study procedure SPECT SPECT/CT 99mTc-etarfolatide . SPECT SPECT/CT scan acquire within 2 week prior EC1456 administration specify Imaging Operations Manual . EC1456 administer pre-operatively intravenous ( IV ) bolus infusion 1 2 time point : 1 . &lt; 8 hour precede surgery 2 . 48±4 hour precede surgery . At 2 time point : 1. within approximately 15 ( ±5 ) minute post-EC1456 administration 2. start surgery , approximately 5 mL whole blood drawn EC1456 analyse . Tissues collect surgery , present , include : sample 1 ovary , endometrium , omentum , ascitic fluid and/or select lesion identify surgeon sponsor . The location sample annotate ex vivo analysis may correlate SPECT/CT image post-surgery . Samples tumor tissue collect time surgery , aliquoted collection vial , place dry ice buffer formalin .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Sodium Pertechnetate Tc 99m</mesh_term>
	<criteria>1 . Subject must ability understand , sign approve informed consent form ( ICF ) . 2 . Subjects must cytologically pathologically confirm advanced ovarian cancer schedule primary , interval , secondary , cytoreductive surgery part standard care treatment ovarian cancer , least 1 lesion remove surgery . 3 . Subject must ≥18 year age . 4 . Subject must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 5 . Subjects central nervous system ( CNS ) metastases must neurologically stable steroid least 14 day preregistration . Subjects asymptomatic CNS metastatic disease without associate edema , shift , requirement steroid antiseizure medication may eligible discussion sponsor 's medical monitor . 6 . Subjects must recover ( baseline/ stabilization ) prior chemo radiotherapy associate acute toxicity must resolve NCI CTCAE v4 Grade 1 less , exception alopecia . 7 . Subject must adequate organ function : Bone marrow reserve : Absolute neutrophil count ≥1.5 × 109/L . Platelets ≥100 × 109/L . Hemoglobin ≥9 g/dL . Cardiac : Left ventricular ejection fraction ( LVEF ) ≥ institutional low limit normal . LVEF must evaluate within 28 day prior dose EC1456 . Cardiac Troponin I within normal limit . Electrocardiogram QT segment correct method Fridericia QTcFridericia ( QTcF ) &lt; 450 msec least 2 3 screen ECG 's . On site determination QTcF may use screen purpose . Hepatic : Total bilirubin ≤1.5 × upper limit normal ( ULN ) . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST 3.0 × ULN , ≤5.0 × ULN subject liver metastasis . Renal : Serum creatinine ≤1.5 × ULN , subject serum creatinine &gt; 1.5 × ULN , creatinine clearance ≥50 mL/min . 8 . Subjects childbearing potential : All woman childbearing potential MUST negative urine serum pregnancy test within 1 week prior 99mTcetarfolatide imaging procedure within 1 week prior dose EC1456 . Women childbearing potential must practice effective method birth control ( e.g. , oral , transdermal injectable contraceptive , intrauterine device [ IUD ] , doublebarrier contraception , diaphragm spermicidal jelly ) duration participation 1 . In opinion investigator , subject 's physical condition might create hardship tolerate radionuclide imaging procedure single administration EC1456 ( e.g. , due pain dyspnea prolong supine position ) . 2 . Use following medication within 6 month prior EC1456 administration : amiodarone , disopyramide , dofetilide , dronedarone , flecanamide , ibutilide , quinidine , sotalol . 3 . Subject comorbid medical condition , opinion investigator , know major impact pharmacokinetics ( PK ) , distribution , metabolism , elimination either small molecule drug conjugate ( SMDC ) . 4 . Subject know active hepatitis B hepatitis C. 5 . Subject active uncontrolled infection ( ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>specimen collection</keyword>
</DOC>